ACC.11 and i2 Summit Late-Breaking Clinical Trials

3010
ACC.11 and i2 Summit Scientific Showcase and Late-Breaking Clinical Trials
ACC/i2 Joint Session
Sunday, April 3, 2011, 8:00 a.m. – 10:00 a.m.
Ernest N. Morial Convention Center, Joint Main Tent: La Nouvelle

Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement in “High Risk” Patients with Aortic Stenosis: The Randomized PARTNER Trial — Craig R. Smith, on behalf of the PARTNER Trial Investigators, Columbia University, New York, NY

Lifetime Cost Effectiveness of Transcatheter Aortic Valve Implantation Compared with Standard Care among Inoperable Patients with Severe Aortic Stenosis: Results from the Randomized PARTNER Trial (Cohort B) — Matthew R. Reynolds, on behalf of the PARTNER Trial Investigators, Beth Israel Deaconess Medical Center, Boston, MA

3013
Late-Breaking Clinical Trials II
ACC/i2 Joint Session
Monday, April 4, 2011, 8:00 a.m. – 9:30 a.m.
Ernest N. Morial Convention Center, Joint Main Tent: La Nouvelle


EVEREST II Randomized Clinical Trial: Two Year Outcomes — Ted Feldman, Elyse Foster, Saibal Kar, William Gray, Andrew Wang, Howard Herrmann, Paul Grayburn, John Lasala, Reginald Low, Wesley Pedersen, Donald Glower, Laura Mauri, The EVEREST II Investigators, Evanston Northwestern Healthcare, Evanston, IL

Medical Therapy with or without Coronary Artery Bypass Graft Surgery in Patients with Ischemic Cardiomyopathy: Results of the Surgical Treatment of Ischemic Heart Failure Trial — Eric J. Velazquez, Kerry Lee, Marek Deja, Anil Jain, George Sopko, Andrey Marchenko, Imtiaz Ali, Gerald Pohost, Sinisa Gradinac, William Abraham, Michael Yii, Dorairaj Prabhakaran, Hanna Szwed, Paolo Ferrazzi, Mark Petrie, Christopher M. O’Connor, Seweryn Wiechowski, Pradit Panchavinnin, Lilin She, Robert H. Jones, Jean-Lucien Rouleau, Duke University, Durham, NC

Influence of Myocardial Viability on Outcome of Patients with Coronary Artery Disease and Left Ventricular Function Undergoing Medical Therapy with and without Surgical Revascularization: Results of the Surgical Treatment for Ischemic Heart Failure Trial — Robert O. Bonow, Gerald Maurer, Kerry Lee, Thomas A. Holly, Philip F. Binkley, Patrice
Radial Artery and Saphenous Vein Patency More than Five Years Following Coronary Artery Bypass Surgery: Results from the Randomized Multicentre Radial Artery Patency Study (RAPS) — Stephen E. Fremes, Saswata Deb, Steve K. Singh, Randi Feder-Elituv, Andreas Laupacis, Eric A. Cohen, Radial Artery Patency Study Investigators, Sunnybrook Health Sciences Centre, Toronto, Canada

Late Breaking Clinical Trials III: Interventional Cardiology
ACC/i2 Joint Session
Monday, April 4, 2011, 10:45 a.m. – 12:15 p.m.
Ernest N. Morial Convention Center, Joint Main Tent: La Nouvelle

Long-Term Outcomes after Use of Drug-Eluting Stents and Bare Metal Stents for the Treatment of Saphenous Vein Graft Lesions: Results of the Randomized ISAR-CABG Trial — Julinda Mehilli, Jürgen Pache, Robert A. Byrne, Steffen Massberg, Jörg Hausleiter, Gert Richardt, Franz-Josef Neumann, Stefanie Schulz, Karl-Ludwig Laugwitz, Melchior Seyfarth, Albert Schömig, Adnan Kastrati, Deutsches Herzzentrum, Munich, Germany

Rival Trial: A Randomized Comparison of Radial versus Femoral Access for Coronary Angiography or Intervention in Patients with Acute Coronary Syndromes — Sanjit S. Jolly, Salim Yusuf, Kari Niemelä, Matti Niemelä, John Cairns, Denis Xavier, Petr Widimsky, Andrzej Budaj, Vicent Valentin, Basil S. Lewis, Alvaro Avezum, Phillippe Gabriel Steg, Sunil V. Rao, Campbell D. Joyner, Susan Chrolavicius, Shamir R. Mehta, on behalf of RIVAL investigators, Population Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Canada

One Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study — Martin B. Leon, Laura Mauri, Alan Yeung, for the RESOLUTE US Investigators, Columbia University Medical Center, New York City, NY, Brigham and Women's Hospital, Boston, MA

A Prospective, Randomized, Investigation of a Novel Platinum Chromium Everolimus-Eluting Coronary Stent: The PLATINUM Trial — Gregg W. Stone, Paul S. Teirstein, Ian T. Meredith, Bruno Farah, Christophe L. Dubois, Robert L. Feldman, Joseph Dens, Nobuhisa Hagiwara, David G. Hurrell, Dominic J. Allocco, Keith D. Dawkins, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY

Renal Insufficiency Following Contrast Media Administration Trial II (REMEDIAL II): Renalguard System In High-risk Patients For Contrast-induced Acute Kidney Injury — Carlo Briguori, Flavio Airoldi, Gabriella Visconti, Amelia Faccio, Marco Valgimigli, Giuseppe Massimo Sangiorgi, Bruno Golia, Gerolama Condorelli, Clinica Mediterranea, Naples, Italy, IRCCS Multimedica, Milan, Italy
Rivaroxaban Compared with Enoxaparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients — Alexander Cohen, Theodore Spiro, Harry Buller, Lloyd Haskell, Dayi Hu, Russell Hull, Alexandre Mebazaa, Geno Merli, Sebastian Schellong, Alex Spyropoulos, Victor Tapson, Bayer HealthCare AG, Leverkusen, Germany

The Comparison of High-dose Angiotensin II Receptor Blocker (ARB) Monotherapy Versus Combination Therapy of ARB with Calcium Channel Blocker on Cardiovascular Events in Japanese Elderly High-Risk Hypertensive Patients: Olmesartan and Calcium Antagonists Randomized (OSCAR) Study — Hisao Ogawa, Shokei Kim-Mitsuyama, Japan, Tomio Jinnouchi, Japan, Hideaki Jinnouchi, Japan, Kunihiko Matsui, Japan, Kikuo Arakawa, Japan, OSCAR study group, Kumamoto University, Kumamoto City, Japan, Fukuoka University, Fukuoka, Japan

Comparison between Valsartan and Amlodipine Regarding Cardiovascular Morbidity and Mortality in Hypertensive Patients with Glucose Intolerance (NAGOYA HEART Study) — Toyoaki Murohara, Takashi Muramatsu, Kunihiro Matsushita, Kentaro Yamashita, Takahisa Kondo, Kengo Maeda, Satoshi Shintani, Nagoya Heart Study Investigators, Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan

Selective Inhibition of Delta Protein Kinase C to Reduce Infarct Size after Primary Percutaneous Intervention for Acute Myocardial Infarction: The PROTECTION-AMI Phase IIb Clinical Trial — A. Michael Lincoff, Mitchell W. Krucoff, Matthew T. Roe, Victor Guetta, John M. Galla, Ellen S. McErlean, Neal S. Kleiman, Harvey White, Andrzej Rynkiewicz, Michael Zelizko, Antonio Fernandez-Ortiz, Dan Atar, Gregory Bell, Cleveland Clinic, Cleveland, OH

The Randomized Comparison of Six-Month versus 12-Month Duration of Dual Antiplatelet Therapy after Implantation of Drug Eluting Stent: From Comparison of Everolimus-versus Sirolimus-Eluting Stents for Coronary Revascularization (EXCELLENT) Trial — Hyeon-Cheol Gwon, Joo-Yong Hahn, Young Bin Song, Kyung Woo Park, Yang-Soo Jang, Hye-Soo Kim, EXCELLENT Investigators, Samsung Medical Center, Seoul, South Korea, Seoul National University Hospital, Seoul, South Korea

Targeted Left Ventricular Lead Placement to Guide Cardiac Resynchronization Therapy in Patients with Heart Failure: A Randomised Prospective Study (Target Study) — Fakhar Z. Khan, Munmohan S. Virdee, Peter J. Pugh, Philip A. Read, Denis O'Halloran, David Begley, Simon P. Fynn, David P. Dutka, Addenbrooke's Hospital, Cambridge, United Kingdom, Papworth Hospital, Cambridge, United Kingdom
Baroreflex Activation Therapy Sustainably Lowers Blood Pressure in Patients with Resistant Hypertension: Results from the Rheos Pivotal Trial — John D. Bisognano, Mitra Nadim, Luis Sanchez, Domenic Sica, George Bakris, University of Rochester Medical Center, Rochester, NY, University of Chicago, Chicago, IL

Reduced Anticoagulation for a Mechanical Heart Valve — John D. Puskas, Reed Quinn, Lilibeth Fermin, Michael McGrath, Marc Gerdisch, Chad Hughes, Thomas Martin, Bobby Kong, Dennis Nichols, Emory University, Atlanta, GA

Specialised Atrial Fibrillation Clinic Reduces Cardiovascular Morbidity and Mortality in Patients with Atrial Fibrillation — Jeroen M. Hendriks, Rianne de Wit, Harry J. Crijns, Hubertus J. Vrijhoef, Martin H. Prins, Ron Pisters, Laurent A. Pison, Yuri Blaauw, Robert G. Tieleman, Maastricht University Medical Centre, Maastricht, The Netherlands

Nt-proBNP Stratified Long-term Follow-up in Outpatient Heart Failure Clinics: A Prospective Randomized Multicenter Trial in the Danish Heart Failure Clinics Network — Morten Schou, Finn Gustafsson, Lars Videbaek, Per R. Hildebrandt, Danish Heart Failure Clinics Network, Odense, Denmark, Hillerod University Hospital, Hillerod, Denmark